Lauren Williams, 74, is trying to raise awareness about the dangers of experimental trials after her husband Malcolm, a ...

For patients with advanced renal cell carcinoma (RCC), there is a sustained clinical benefit with pembrolizumab plus axitinib ...

CytomX Therapeutics' innovative cancer therapies show promise with the CX-2051 and CX-801 trials. Explore the potential of ...

Two days after being taken to hospital Malcolm was diagnosed with immunotherapy-related myocarditis, a rare but known complication of the drug he was trialling and he was started on high dose steroids ...

Eftilagimod alfa shows promise as a novel immunotherapy for head and neck cancer patients with low PD-L1 expression, offering ...

A two-drug combination for treating advanced kidney cancer has shown sustained and durable clinical benefit in more than five ...

They evaluated pembrolizumab in patients with resectable stage II-IV (M0) cSCC. Patients received 200 mg pembrolizumab every 3 weeks for 4 cycles, followed by 18F-labeled fluorodeoxyglucose-positron ...

A study reveals real-world outcomes of neoadjuvant immune checkpoint inhibitors in nonmetastatic colon cancer, highlighting ...

Adverse events reported in oncology clinical trials don’t always match what patients experience. What is behind this ...

A man who 'jumped at the opportunity' to take part in a miracle drug trial died with days of starting the treatment, says his ...

These data support the use of sacituzumab plus pembrolizumab as a potential new standard of care,” said Sara Tolaney, MD.

Zara McCormick, 36, from the U.K. village of Gee Cross in Tameside, received the diagnosis on the same week as her son's ...